•Novartis reports positive phase 3 data on ianalumab for Sjögren’s•Tenpoint introduces YUVEZZI telehealth prescribing program•i-Lumen reports new i-SIGHT data on retinal bioelectric stimulation for dry AMD•IMVIONIX debuts with acquisition of BEOVU's North American rights •VeonGen on track for phase 3 Stargardt trial after FDA meeting•Novartis reports positive phase 3 data on ianalumab for Sjögren’s•Tenpoint introduces YUVEZZI telehealth prescribing program•i-Lumen reports new i-SIGHT data on retinal bioelectric stimulation for dry AMD•IMVIONIX debuts with acquisition of BEOVU's North American rights •VeonGen on track for phase 3 Stargardt trial after FDA meeting
HEADLINES
FEATURED
Pending transaction includes phase 3 funding for OLN324, an investigational bispecific antibody under evaluation for wet AMD and DME.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
